ATE275394T1 - R- und s- enantiomere getrennteteile enthaltende dosierungsformen - Google Patents

R- und s- enantiomere getrennteteile enthaltende dosierungsformen

Info

Publication number
ATE275394T1
ATE275394T1 AT98910863T AT98910863T ATE275394T1 AT E275394 T1 ATE275394 T1 AT E275394T1 AT 98910863 T AT98910863 T AT 98910863T AT 98910863 T AT98910863 T AT 98910863T AT E275394 T1 ATE275394 T1 AT E275394T1
Authority
AT
Austria
Prior art keywords
enantiomeric
dosage forms
dosage form
separate parts
enantiomers
Prior art date
Application number
AT98910863T
Other languages
English (en)
Inventor
Julian Clive Gilbert
Andrew J M Richards
Hazel Judith Bardsley
Original Assignee
Arakis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9704978.7A external-priority patent/GB9704978D0/en
Priority claimed from GBGB9719261.1A external-priority patent/GB9719261D0/en
Application filed by Arakis Ltd filed Critical Arakis Ltd
Application granted granted Critical
Publication of ATE275394T1 publication Critical patent/ATE275394T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98910863T 1997-03-11 1998-03-11 R- und s- enantiomere getrennteteile enthaltende dosierungsformen ATE275394T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9704978.7A GB9704978D0 (en) 1997-03-11 1997-03-11 Dosage forms
GBGB9719261.1A GB9719261D0 (en) 1997-09-10 1997-09-10 Dosage forms
PCT/GB1998/000726 WO1998040053A1 (en) 1997-03-11 1998-03-11 Dosage forms comprising separate portions of r- and s-enantiomers
US09/038,873 US6056968A (en) 1997-03-11 1998-03-11 Pharmaceutical drug dosage forms providing different release rates

Publications (1)

Publication Number Publication Date
ATE275394T1 true ATE275394T1 (de) 2004-09-15

Family

ID=27268767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98910863T ATE275394T1 (de) 1997-03-11 1998-03-11 R- und s- enantiomere getrennteteile enthaltende dosierungsformen

Country Status (15)

Country Link
US (2) US6056968A (de)
EP (1) EP0969818B1 (de)
JP (1) JP2001514651A (de)
CN (1) CN1251987A (de)
AT (1) ATE275394T1 (de)
AU (1) AU741821B2 (de)
BR (1) BR9808325A (de)
CA (1) CA2285407C (de)
DE (1) DE69826113T2 (de)
ES (1) ES2227814T3 (de)
HU (1) HUP0000759A3 (de)
IL (1) IL131713A (de)
NO (1) NO994412L (de)
PL (1) PL335619A1 (de)
WO (1) WO1998040053A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
JP2002531431A (ja) * 1998-12-02 2002-09-24 ダーウィン・ディスカバリー・リミテッド 治療用製品およびその使用
WO2000043003A1 (en) * 1999-01-21 2000-07-27 Darwin Discovery Limited The therapeutic use of r-warfarin as anticoagulant
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
EP1313460A2 (de) * 1999-11-09 2003-05-28 Darwin Discovery Limited Therapeutische verwendung und formulierungen von (-)-tramadol
DE10004926A1 (de) 2000-02-04 2001-08-09 Gruenenthal Gmbh Verfahren zur enzymatischen Racematspaltung von Aminomethyl-Aryl-Cyclohexanol-Derivaten
DE60107393T2 (de) 2000-03-01 2005-12-01 Euro-Celtique S.A. Verwendung von tramadol zur herstellung eines arzneimittels zur behandlung von funktionelle gastrointestinale krankenheiten
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
JP2004513091A (ja) * 2000-10-03 2004-04-30 ペンウェスト ファーマシューティカルズ カンパニー 異なる速度の複数の医薬活性成分の送達系
CA2426811A1 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
DE10108122A1 (de) 2001-02-21 2002-10-02 Gruenenthal Gmbh Arzneimittel auf Basis von Tramadol
IN191028B (de) * 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
AU2003288608A1 (en) * 2002-12-20 2004-07-14 Ranbaxy Laboratories Limited Controlled release, multiple unit drug delivery systems
ES2293223T3 (es) * 2003-02-10 2008-03-16 Shire Canada Inc. Composiciones enantiomericas de anfetamina para el tratamiento de adhd.
WO2004103361A2 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited A pharmaceutical dosage form of citalopram
CA2528249C (fr) * 2003-06-06 2013-03-05 Ethypharm Comprime orodispersible multicouche
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性(biosynchronous)経皮的薬物送達
US20080038344A1 (en) * 2004-10-01 2008-02-14 Nippon Zoki Pharmaceutical Co., Ltd. Solid Pharmaceutical Preparation
CA2616204C (en) 2005-09-09 2015-12-01 Labopharm Inc. Sustained drug release composition
EP1976488A4 (de) * 2006-01-12 2010-02-10 Wockhardt Ltd Zusammensetzungen aus alfuzosin mit verzögerter freisetzung
WO2007114376A1 (ja) * 2006-03-30 2007-10-11 Nippon Zoki Pharmaceutical Co., Ltd. 固形医薬製剤
CA2677691C (en) 2007-02-12 2012-07-31 David Bar-Or Reducing side effects of tramadol
KR20140054312A (ko) * 2007-02-12 2014-05-08 디엠아이 바이오사이언시스 인코포레이티드 조루 및 발기부전을 동시에 치료하는 방법
WO2008122049A2 (en) 2007-04-02 2008-10-09 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
EP3250258A4 (de) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Verfahren und systeme zur wirkstofffreisetzung
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. 経皮薬剤送達の装置及び方法
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818541A (en) * 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
US5145866A (en) * 1991-04-22 1992-09-08 Hoechst-Roussel Pharmaceuticals Incorporated Method of treating anxiety with the aid of r(+)-3-amino-1-hydroxy-pyrrolidin-2-one
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4319438C1 (de) * 1993-06-11 1994-06-01 Gerd Dr Dr Geislinger Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren
GB9412689D0 (en) * 1994-06-23 1994-08-10 Chiroscience Ltd Cytotoxic agent and its use

Also Published As

Publication number Publication date
HUP0000759A3 (en) 2000-11-28
CN1251987A (zh) 2000-05-03
AU741821B2 (en) 2001-12-13
NO994412D0 (no) 1999-09-10
IL131713A (en) 2004-08-31
WO1998040053A1 (en) 1998-09-17
US6056968A (en) 2000-05-02
DE69826113D1 (de) 2004-10-14
JP2001514651A (ja) 2001-09-11
IL131713A0 (en) 2001-03-19
ES2227814T3 (es) 2005-04-01
US6221394B1 (en) 2001-04-24
AU6508998A (en) 1998-09-29
PL335619A1 (en) 2000-05-08
BR9808325A (pt) 2000-05-16
NO994412L (no) 1999-10-20
HUP0000759A2 (hu) 2000-10-28
EP0969818A1 (de) 2000-01-12
CA2285407A1 (en) 1998-09-17
CA2285407C (en) 2006-08-01
DE69826113T2 (de) 2005-01-20
EP0969818B1 (de) 2004-09-08

Similar Documents

Publication Publication Date Title
ATE275394T1 (de) R- und s- enantiomere getrennteteile enthaltende dosierungsformen
PT1439829E (pt) Medicamento contendo 3-(3-dimetilamino-1-etil-2-metilpropil)-fenol proporcionando libertacao retardada da substancia activa
PT1448591E (pt) 17alfa-alquil-17beta-oxi-estratrieno e produtos intermediários para a sua preparação, utilização do 17alfaalquil-17beta-oxi-estratrieno para a preparação de medicamentos e preparações farmacêuticas
NO20041740L (no) Tidsstyrt vedvarende frigivelses multipartikulaere doseringsformer av propranolol
ATE374194T1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
DK1162982T3 (da) Anvendelse af stabiliserede oligonucleotider til fremstilling af et lægemiddel med antitumoral virkning
ZA992951B (en) N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders.
IS7497A (is) (1a,3a,5a)(3-amínómetýl bísýkló[3.2.0]hept-3-ýl)l-ediksýra, lyfjasamsetningar og notkun efnasambands til framleiðslu á lyfjum
MA25567A1 (fr) Nouvelle composition et son utilisation
DE60034240D1 (de) Drogen zur behandlung maligner tumoren
NO20054739L (no) Metode for okning av oral biotilgjengelighet av S-2'-("1-(2-etylbutyl)cyklo-heksyl!carbonyl!amino)fenyl!-2-metylpropanetioat
DK1144386T3 (da) Polymorf form af telmisartan, fremgangsmåde til fremstilling deraf og anvendelse deraf til fremstilling af et lægemiddel
MY124146A (en) Novel 2-(iminomethyl) amino-phenyl derivatives, preparation, application as medicines and pharmaceutical compositions containing same
AU2003293593A1 (en) Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration
WO2000059489A3 (en) Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
ES2138950T1 (es) Nuevo procedimiento.
DK0966285T3 (da) Anvendelse af (+)mefloquin til behandling af malaria
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
EE200100596A (et) Ülipuhas (1R,2S,4R)-(-)-2-[(2'-{N,N-dimetüülamino}etoksü)]-2-[fenüül]-1,7,7-tri[metüül]bitsüklo[2.2.1 ]heptaan ja selle farmatseutiliselt vastuvõetavad happeliitsoolad ning nimetatud ühendite, samutiravimite, mis sisaldavad üks või enam nimetatud üh
HK1086819A1 (en) 2-(butyl-1-sulfonylamino)-n-(1(r)-(6-methoxy-pyridin-3-yl)-propyl)-benzamid, the use thereof in the form of drug an pharmaceutical preparations containing said compound
DK1151746T3 (da) Mikro-kapsler til vedvarende frigivelse af lægemidler
DK1071397T3 (da) Levosimendan-holdige lægemidler til oral indgivelse med kontrolleret frisætning af det aktive middel
NO20022896L (no) Substituerte 1- og 2-naftol mannich baser
ATE303135T1 (de) Pharmazeutische formulierungen zur gesteuerten freisetzung von 4-amino-6,7-dimethoxy-2-(5-

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties